Jemperli (Dostarlimab) for Endometrial Cancer

Overview
Jemperli is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of endometrial cancer (a cancer that begins in the lining of the uterus). It is used along with the chemotherapy drugs carboplatin and paclitaxel for individuals with advanced or recurrent endometrial cancer. Jemperli is also used on its own for individuals with mismatch repair deficient (dMMR) endometrial cancer that has returned or spread after earlier treatment and cannot be treated with surgery or radiation. Mismatch repair deficient means the cancer cells have trouble fixing DNA mistakes, making them grow uncontrollably. Jemperli is also known as dostarlimab.

Jemperli works by blocking a protein called PD-1, which can stop the immune system from attacking cancer cells. By blocking PD-1, Jemperli helps the immune system find and destroy these cells.

How do I take it?
Prescribing information states that Jemperli is given as an intravenous (IV) infusion, meaning it is delivered directly into a vein.

• For advanced or recurrent EC (with carboplatin and paclitaxel), treatment is generally given every three weeks for six cycles at a lower dosage. Afterward, it transitions to a higher dosage every six weeks as a single-agent therapy.
• For dMMR recurrent or advanced EC as a single agent, the regimen starts with a lower dosage every three weeks for four cycles, followed by a higher dosage every six weeks thereafter.

The infusion schedule depends on the stage of treatment, and the medication must be taken exactly as directed by a health care provider.

Side effects
Common side effects of Jemperli include feeling tired, nausea (upset stomach), diarrhea, anemia (low red blood cell levels), and changes in lab test results like low sodium or high alkaline phosphatase (a liver-related enzyme).

Rare but serious side effects may occur, including immune system problems where the body attacks its own organs. These can include pneumonitis (lung inflammation), colitis (intestinal inflammation), hepatitis (liver inflammation), and endocrinopathies (hormone gland problems). Reactions during the infusion may also happen. Jemperli may cause complications for individuals who have received allogeneic hematopoietic stem cell transplantation. Jemperli may harm a developing baby, so individuals who could become pregnant should use effective birth control.

For more information about this treatment, visit:

Label: Jemperli — Dostarlimab Injection — DailyMed